AMRNAmarin Corporation plc

AMRN Stock Price, Valuation & Chart | Amarin Corporation plc

Compare

$13.700-0.14 (-1.05%)

At close · 02 Sept 2026, 08:00 pm

Sector: Healthcare Industry: Biotechnology AMRN intrinsic value AMRN calculated fair value vs price

Overview Financials Dividends Ratios

AMRN Historical price chart

AMRN Key Stats

Fair Value

Disclaimer

Disclaimer: This fair value estimate is for informational purposes only and should not be considered as investment advice. Fair value calculations are based on DCF (Discounted Cash Flow), P/E Multiple, and P/S Multiple models and assumptions that may not reflect actual market conditions. Always conduct your own research and consult with a financial advisor before making investment decisions.

Unlock

Market Capitalization283.35M

PE Ratio-137.0

EPS-0.1

Trading Volume45.53K

Today's High/Low14.02/13.67

Dividend Yield0.00

52 Week High/Low20.9/12.96

Shares Outstanding20.68M

AMRN Financial Statement

AMRN Analyst ratings

AMRN Analysis & performance metrics

AMRN Company profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United…

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, Germany, Canada, Lebanon, and the United Arab Emirates. Its lead product is VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult…

AMRN Management team

Name

Position

Nabil Abadir

Chief Medical Officer of Global Medical Affairs

Steven B. Ketchum Ph.D.

Executive Vice President, President of Research & Development and Chief Scientific Officer

Jonathan N. Provoost

Executive Vice President, Chief Legal & Compliance Officer and Secretary

Laurent Abuaf

President of Europe & Senior Vice President

Jordan Zwick

Senior Vice President of Corporate Business Development & Investor Relations

Aaron D. BergCEO

Chief Executive Officer, President & Director

Peter L. FishmanCFO

Chief Financial Officer

David Keenan Ph.D.

Executive Vice President of Technical Operations & President of Europe

Name

Position

Nabil Abadir

Chief Medical Officer of Global Medical Affairs

Steven B. Ketchum Ph.D.

Executive Vice President, President of Research & Development and Chief Scientific Officer

Jonathan N. Provoost

Executive Vice President, Chief Legal & Compliance Officer and Secretary

Laurent Abuaf

President of Europe & Senior Vice President

Jordan Zwick

Senior Vice President of Corporate Business Development & Investor Relations

Aaron D. BergCEO

Chief Executive Officer, President & Director

Peter L. FishmanCFO

Chief Financial Officer

David Keenan Ph.D.

Executive Vice President of Technical Operations & President of Europe

Management Team

Nabil Abadir

Chief Medical Officer of Global Medical Affairs

Steven B. Ketchum Ph.D.

Executive Vice President, President of Research & Development and Chief Scientific Officer

Jonathan N. Provoost

Executive Vice President, Chief Legal & Compliance Officer and Secretary

Laurent Abuaf

President of Europe & Senior Vice President

Jordan Zwick

Senior Vice President of Corporate Business Development & Investor Relations

Aaron D. BergCEO

Chief Executive Officer, President & Director

Peter L. FishmanCFO

Chief Financial Officer

David Keenan Ph.D.

Executive Vice President of Technical Operations & President of Europe

Management

Nabil Abadir

Chief Medical Officer of Global Medical Affairs

Steven B. Ketchum Ph.D.

Executive Vice President, President of Research & Development and Chief Scientific Officer

Jonathan N. Provoost

Executive Vice President, Chief Legal & Compliance Officer and Secretary

Laurent Abuaf

President of Europe & Senior Vice President

Jordan Zwick

Senior Vice President of Corporate Business Development & Investor Relations

Aaron D. BergCEO

Chief Executive Officer, President & Director

Peter L. FishmanCFO

Chief Financial Officer

David Keenan Ph.D.

Executive Vice President of Technical Operations & President of Europe

Total 8 executives

AMRN Frequently asked questions

What is Amarin Corporation plc (AMRN) Stock Price?

Current stock price of Amarin Corporation plc (AMRN) stock is $13.700. The stock price is -1.05% lower in the session. The intraday range can be seen from this page. Volume of Amarin Corporation plc (AMRN) stock is 45.53K.

Last updated at 02 Sept 2026, 08:00 pm.

Why is the Amarin Corporation plc (AMRN) stock price going up or down today?

The stock price of Amarin Corporation plc (AMRN) can change with earnings, company news, and overall market sentiment. Amarin Corporation plc operates in the Healthcare / Biotechnology market, so sector-wide moves can also affect the share price. Use the live price, percentage change, and volume on this page to judge whether a move looks meaningful.

Is the Amarin Corporation plc stock expensive at its current price?

Whether Amarin Corporation plc looks expensive depends on valuation metrics versus its growth outlook. The P/E ratio shown for AMRN on this page is -137.00. EPS on this page is -0.10. Compare those figures with peers and growth expectations before deciding if the current Amarin Corporation plc price is justified.

How has the stock price of Amarin Corporation plc (AMRN) performed historically?

Historical performance for Amarin Corporation plc (AMRN) is shown on the price chart on this page. Review multi-period moves alongside volume to see how AMRN reacted to past earnings and market events.

Should I buy Amarin Corporation plc (AMRN) stock, at this price?

Buying Amarin Corporation plc (AMRN) depends on your risk tolerance, time horizon, and portfolio needs. As a Healthcare name, weigh the live quote, key stats, and valuation links on this page rather than a single price point.